Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828059 | 1.00 | KCNH2 (0.44) | KCNH2STK17BSTK17ACA12CA1 | |
| SCHEMBL24936290 | 0.86 | STK17B (0.46) | KCNH2STK17BSTK17ACA12CA1 | |
| SCHEMBL30522690 | 0.86 | STK17B (0.46) | KCNH2STK17BSTK17ACA12CA1 | |
| SCHEMBL24485511 | 0.85 | KCNH2 (0.52) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL30615075 | 0.81 | KCNH2 (0.37) | KCNH2BRD4ATMSTING1 | |
| SCHEMBL29045179 | 0.80 | CHEK1 (0.35) | KCNH2 | |
| SCHEMBL19007377 | 0.80 | DRD2 (0.46) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL24936245 | 0.80 | STK17B (0.41) | KCNH2STK17BSTK17ACA12CA1 | |
| SCHEMBL24485105 | 0.75 | STK17B (0.47) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL29827348 | 0.74 | STK17B (0.41) | KCNH2STK17BSTK17ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | KCNH2 2700/4885STK17B 529/4885STK17A 592/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | KCNH2 2700/4885STK17B 529/4885STK17A 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.